Hormonal Therapy in Nonmetastatic Breast Cancer
Breast cancer is one of the few cancers which are under hormonal regulation, and the manipulation of hormonal control has shown marvelous results. Role of hormones in breast cancer was first highlighted when it was observed that in certain patients, the diseased regressed with the onset of menopause. This was further consolidated when similar regression was observed by Beaston, that in many premenopausal women the disease regresses after surgical oophorectomy. Hormone-positive breast cancers account for nearly two third of total breast cancer patients. Hormonal therapy has proven its effectiveness in both adjuvant and advanced settings and also known to be devoid of major toxicities.
KeywordsBreast Cancer Endometrial Cancer Premenopausal Woman National Comprehensive Cancer Network National Comprehensive Cancer Network
- 2.Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351(9114):1451–67.Google Scholar
- 12.Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1996;348(9036):1189–96.Google Scholar
- 13.Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat. 1997;44(3):211–5.PubMedCrossRefGoogle Scholar
- 14.NCCN clinical practice guidelines in oncology (NCCN guidelines), breast cancer (version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
- 16.Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–8.PubMedCentralPubMedCrossRefGoogle Scholar
- 19.Dubsky PC, Jakesz R, Mlineritsch B, et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2012;30(7):722–8.PubMedCrossRefGoogle Scholar
- 26.Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31sl: abstr 5.Google Scholar
- 27.Group LH-aiEBCO, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711–23.PubMedCrossRefGoogle Scholar